Phase 2 N=53 A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
Lymphoma
Primary: Safety of LO-CHOP — 70; 0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 Reducing Frailty for Older Cancer Survivors Using Supplements
Frailty · Inflammation
Primary: Recruitment Feasibility: Rates of Consent — 0.375 proportion of participants
Phase 2 N=13 Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis
Exocrine Pancreatic Insufficiency · Cystic Fibrosis
Primary: Safety of Adrulipase — 2 Participants
Phase 2 N=20 Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Peritoneal Carcinomatosis
Primary: Overall Survival — 22.1 Months
Phase 2 N=224 Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload
Transfusion-dependent Anemia
Primary: Percentage of Overall Compliance Using Stick Pack or Tablet Counts in Iron Chelation Therapy (ICT)-naïve Participants During the Core Phase — 89.45; 91.78 percentage of…
Phase 2 N=44 Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic Leukemia
Primary: Number of Patients With Complete Response (CR) — 11 Participants
Phase 2 N=48 Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD) · Type 2 Diabetes (T2DM)
Primary: Change in Intrahepatic Triglycerides (IHTG) Quantified by Proton Magnetic Resonance and Spectroscopy (¹H-MRS) — -8.7; -3.0 percentage decrease from baseline
Phase 2 N=9 Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Thyroid Cancer · Anaplastic Thyroid Cancer · Undifferentiated Thyroid Cancer
Primary: Number of Participants With Overall Response (OR) — 0 Participants
Phase 2 N=24 Safety and Efficacy of CD10367 in Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Area Under the Curve (AUC) of Total Sum Score (Sum of Erythema, Scaling and Induration Scores) — 103.4; 101.7; 118.0; 118.6 score on a scale*days
Phase 2 N=44 Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease
Sickle Cell Disease
Primary: Maximum Plasma Concentration — 0.5835; 0.7425; 0.2186; 0.7128 ng/mL
Phase 2 N=37 Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis
Primary Biliary Cirrhosis
Primary: Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis…
Phase 2 N=62 Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
Recurrent Head and Neck Squamous Cell Carcinoma
Primary: Number of Participants With Progression-Free Survival (PFS) — 27 Participants
Phase 2 N=92 Minnesota HealthSolutions Cellular Car Seat Study
Child Safety Seat Harness Tension
Primary: Number of Participants With Installation Errors — 21; 41; 17; 32 Participants — p=<.001
Phase 2 N=154 A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Primary: Proportion of Patients With a Given Tumour Genetic and Proteomic Marker at the Point of Disease Progression — 2.0; 3.9; 2.0; 3.9 Percentage of participants
Phase 2 N=30 ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment
HIV Infection
Primary: Number of Participants With Adverse Events — 5; 15; 7; 4 Participants